Similarly, an analysis of 1173 BC patients found that extreme CIN was associated with a better prognosis in estrogen receptor-negative (ER-)/HER2-negative BC patients, suggesting that extreme CIN could serve as a favorable prognostic marker [13]. This evidence concerns the gene ERBB2 and breast cancer.